期刊文献+

(1R,2S)-2-(3,4-二氟苯基)环丙胺扁桃酸盐单晶的制备及结构解析 被引量:1

Growth and Crystal Structure of(1R,2S)-2-(3,4-Difluorophenyl) Cyclopropanamine(S)-(carboxylato(phenyl) methyl) Holmium Single Crystals
原文传递
导出
摘要 目的制备(1R,2S)-2-(3,4-二氟苯基)环丙胺扁桃酸盐(TCGM3)单晶,并对其空间结构进行解析。方法通过优化溶剂、温度等结晶工艺参数,制备TCGM3单晶,采用单晶X射线衍射技术对其进行空间结构解析。结果外形完整的TCGM3单晶可通过甲醇体系室温蒸发4 d得到。单晶X射线衍射结果表明TCGM3晶胞属于正交晶系,P212121空间群,结构偏离因子R=0.04,分子式为C_(17)H_(17)F_2NO_3,相对分子质量为321.32 g·mol^(-1),立体构型与预测构型一致。结论通过单晶培养及对其进行单晶X射线衍射分析和结构解析,确证了TCGM3的空间结构。 OBJECTIVE To prepare single crystals of(1 R, 2 S)-2-(3, 4-difluorophenyl) cyclopropanamine(S)-(carboxylato(phenyl) methyl) holmium(TCGM3), and to confirm the corresponding spatial structure. METHODS Crystallization conditions including solvents and temperature were investigate to grow single crystals of TCGM3. Then, the crystal structure was solved by single crystal X-ray diffraction(SXRD) analysis. RESULTS Perfect single crystals of TCGM3 had been grown by evaporation in methnaol for 4 d at ambient temperature. SXRD confirmed the the orthorhombic lattice with space group P212121 in TCGM3 crystal with a refinement value(R) of 0.04. Moreover, the chemical formula and relative molecular mass were C_(17)H_(17)F_2NO_3 and 321.32 g·mol^(-1), respectively. The measured crystal structure was in good agreement with the predicted one. CONCLUSION Single crystals of TCGM3 are obtained. On this basis, crystal structure of TCGM3 is characterized through SXRD.
出处 《中国现代应用药学》 CAS CSCD 北大核心 2018年第1期1-4,共4页 Chinese Journal of Modern Applied Pharmacy
基金 国家自然科学基金项目(21406071) 中央高校基本科研业务项目(22A201514006)
关键词 TCGM3 单晶 单晶X射线衍射 结构解析 TCGM3 single crystal SXRD structure characterization
  • 相关文献

参考文献4

二级参考文献20

  • 1FDA. Guidance for Industry Drug Substance,Chemistry, Manufacturing and Controls Information [ S ] ,2004. 被引量:1
  • 2EMEA. Note For Guidance On Chemistry of The New Active Substance [ S ] ,2003. 被引量:1
  • 3LYU Y, DU G H. Polymorphic Drugs(晶型药物) [M]. Beijing: People’s Medical Publishing House, 2009. 被引量:1
  • 4ZHANG X Y, LIU W. Transformation of polymorphism in the process of rubbing [J]. 山东医药工业, 2001, 20(1): 29-30. 被引量:1
  • 5TAWASHI R. Aspirin: dissolution rates of two polymorphic forms [J]. Science, 1968, 160(823): 76. 被引量:1
  • 6ZOU Y G, LI Y S, BI X F. Different polymorphic forms of rfandin [J].中国药物化学杂志, 1992, 2(3): 68-72. 被引量:1
  • 7PARTINEN M, HIRVONEN K, JAMA L, et al. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: A polysomnographic dose-finding study-The PRELUDE study [J]. Sleep Med, 2006, 7(5): 407-417. 被引量:1
  • 8?ASZCZ M, TRZCI?SKA K, KUBISZEWSKI M, et al. Stability studies and structural characterization of pramipexole [J]. J Pharm Biomed Anal, 2010, 53(4): 1033-1036. 被引量:1
  • 9PATEL D A, KUMAR R, DWIVEDI S D. Process for preparing (S)-pramipexole and its intermediates [P]. WO2008/041240A1, 2008. 被引量:1
  • 10KANWAR S, PATEL K, DEO K, et al. Process for the preparation of pramipexole and new anhydrous forms of its dihydrochloride [P]. WO2006/117614A1, 2006. 被引量:1

共引文献4

同被引文献10

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部